Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 2, 2014, Pages 126-136

  Farr, Sarah ^a,b   Taher, Jennifer ^a,b   Adeli, Khosrow ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein; Chylomicron; Dyslipidemia; Glucagon like peptide 1; Hepatic steatosis; Insulin resistance; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B48; ASCORBIC ACID; CHYLOMICRON; EXENDIN 4; EXENDIN9-39; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; SITAGLIPTIN; TASPOGLUTIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VILDAGLIPTIN; LIPOPROTEIN;

ARTICLE; AUTOPHAGY; CARDIOVASCULAR RISK; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID OXIDATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTESTINE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; POSTPRANDIAL STATE; STOMACH EMPTYING; ANIMAL; CARDIOVASCULAR DISEASES; FATTY LIVER; LIPID METABOLISM; LIVER; METABOLISM; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; CHYLOMICRONS; DYSLIPIDEMIAS; FASTING; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN RESISTANCE; INTESTINES; LIPID METABOLISM; LIPOPROTEINS; LIVER; POSTPRANDIAL PERIOD; RISK FACTORS; TRIGLYCERIDES;

EID: 84906259634     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140505125300     Document Type: Article

References (99)

1. Perley, M.J.; Kipnis, D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J. Clin. Invest., 1967, 46, 1954.
2. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132, 2131-2157.
3. Nauck, M.A.; Heimesaat, M.M.; Orskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest., 1993, 91, 301-307.
4. Nauck, M.A.; Heimesaat, M.M.; Behle, K.; Holst, J.J.; Nauck, M.S.; Ritzel, R.; Hüfner, M.; Schmiegel, W.H. Effects of glucagonlike peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab., 2002, 87, 1239-1246.
5. Lee, Y.; Shin, S.; Shigihara, T.; Hahm, E.; Liu, M.; Han, J.; Yoon, J.; Jun, H. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes, 2007, 56, 1671-1679.
6. Hardikar, A.A.; Wang, X.Y.; Williams, L.J.; Kwok, J.; Wong, R.; Yao, M.; Tuch, B.E. Functional maturation of fetal porcine betacells by glucagon-like peptide 1 and cholecystokinin. Endocrinology, 2002, 143, 3505-3514.
7. Li, Y.; Hansotia, T.; Yusta, B.; Ris, F.; Halban, P.A.; Drucker, D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem., 2003, 278, 471-478.
8. Flint, A.; Raben, A.; Astrup, A.; Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest., 1998, 101, 515-520.
9. Meier, J.J.; Gallwitz, B.; Salmen, S.; Goetze, O.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2003, 88, 2719-2725.
10. Hansen, L.; Deacon, C.F.; Orskov, C.; Holst, J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology, 1999, 140, 5356-5363.
11. Deacon, C.F.; Nauck, M.A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44, 1126-1131.
12. Kolterman, O.G.; Kim, D.D.; Shen, L.; Ruggles, J.A.; Nielsen, L.L.; Fineman, M.S.; Baron, A.D. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health. Syst. Pharm., 2005, 62, 173-181.
13. Agersø, H.; Jensen, L.B.; Elbrønd, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 2002, 45, 195-202.
14. Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006, 368, 1696-1705.
15. Adiels, M.; Borén, J.; Caslake, M.J.; Stewart, P.; Soro, A.; Westerbacka, J.; Wennberg, B.; Olofsson, S.; Packard, C.; Taskinen, M. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1697-1703.
16. Curtin, A.; Deegan, P.; Owens, D.; Collins, P.; Johnson, A.; Tomkin, G.H. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol., 1996, 33, 205-210.
17. Yu, K.C.; Mamo, J.C. Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Clin. Sci., 2000, 98, 183.
18. Haffner, S. M.; Lehto, S.; Rönnemaa, T.; Pyörälä, K.; Laakso, M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N. Engl. J. Med., 1998, 339, 229-234.
19. Bansal, S.; Buring, J.E.; Rifai, N.; Mora, S.; Sacks, F.M.; Ridker, P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007, 298, 309-316.
20. Rivellese, A.A.; De Natale, C.; Di Marino, L.; Patti, L.; Iovine, C.; Coppola, S.; Del Prato, S.; Riccardi, G.; Annuzzi, G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J. Clin. Endocrinol. Metab., 2004, 89, 2153-2159.
21. Lewis, G.F.; O'meara, N.M.; Soltys, P.A.; Blackman, J.D.; Iverius, P.H.; Druetzler, A.F.; Getz, G.S.; Polonsky, K.S. Postprandial Lipoprotein Metabolism in Normal and Obese Subjects: Comparison after the Vitamin A Fat-Loading Test. J. Clin. Endocrinol. Metab., 1990, 71, 1041-1050.
22. Duez, H.; Lamarche, B.; Uffelman, K.D.; Valero, R.; Cohn, J.S.; Lewis, G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1357-1363.
23. Haidari, M.; Leung, N.; Mahbub, F.; Uffelman, K.D.; Kohen-Avramoglu, R.; Lewis, G.F.; Adeli, K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J. Biol. Chem. 2002, 277, 31646-31655.
24. Vine, D.F.; Takechi, R.; Russell, J.C.; Proctor, S.D. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulinresistant JCR:LA-cp rat: Increased atherogenicity for the metabolic syndrome. Atherosclerosis, 2007, 190, 282-290.
25. Zoltowska, M.; Ziv, E.; Delvin, E.; Sinnett, D.; Kalman, R.; Garofalo, C.; Seidman, E.; Levy, E. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes. Diabetes, 2003, 52, 2539-2545.
26. Yoder, S.M.; Yang, Q.; Kindel, T.L.; Tso, P. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am. J. Physiol. Gastr. L. 2009, 297, 299-305.
27. Herrmann, C.; Göke, R.; Richter, G.; Fehmann, H.C.; Arnold, R.; Göke, B. Glucagon-like peptide-1 and glucose-dependent insulinreleasing polypeptide plasma levels in response to nutrients. Digestion, 1995, 56, 117-126.
28. Edfalk, S.; Steneberg, P.; Edlund, H.; fakulteten, M.; Umeå, c.f. Umeå universitet Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes, 2008, 57, 2280-2287.
29. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med., 2005, 11, 90-94.
30. Hsieh, J.; Longuet, C.; Baker, C.L.; Qin, B.; Federico, L.M.; Drucker, D.J.; Adeli, K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 2010, 53, 552-561.
31. Qin, X.; Shen, H.; Liu, M.; Yang, Q.; Zheng, S.; Sabo, M.; D'Alessio, D.A.; Tso, P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastr. L. 2005, 288, G943-949.
32. Meier, J.J.; Gethmann, A.; Götze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W. E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006, 49, 452-458.
33. Xiao, C.; Bandsma, R.H.J.; Dash, S.; Szeto, L.; Lewis, G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 1513.
34. Vilsbøll, T.; Krarup, T.; Deacon, C.F.; Madsbad, S.; Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 2001, 50, 609-613.
35. Tremblay, A.J.; Lamarche, B.; Deacon, C.F.; Weisnagel, S.J.; Couture, P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes. Metab. 2011, 13, 366-373.
36. Matikainen, N.; Mänttäri, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning, B. E.; Foley, J. E.; Taskinen, M. R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49, 2049-2057.
37. Schwartz, S. L.; Ratner, R.E.; Kim, D.D.; Qu, Y.; Fechner, L.L.; Lenox, S.M.; Holcombe, J.H. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin. Ther., 2008, 30, 858-867.
38. Bunck, M.C.; Cornér, A.; Eliasson, B.; Heine, R.J.; Shaginian, R.M.; Wu, Y.; Yan, P.; Smith, U.; Yki-Järvinen, H.; Diamant, M.; Taskinen, M. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis, 2010, 212, 223-229.
39. Schwartz, E.A.; Koska, J.; Mullin, M.P.; Syoufi, I.; Schwenke, D.C.; Reaven, P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010, 212, 217-222.
40. Cummings, B.P.; Strader, A.D.; Stanhope, K.L.; Graham, J.L.; Lee, J.; Raybould, H.E.; Baskin, D.G.; Havel, P. J. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology, 2010, 138, 2437-2446. e1.
41. Beckman, T.R.; Beckman, L.M.; Earthman, C.P. Changes in Gastrointestinal Hormones and Leptin after Roux-en-Y Gastric Bypass Procedure: A Review. J. Am. Diet. Assoc., 2010, 110, 571-584.
42. Nguyen, N.T.; Varela, E.; Sabio, A.; Tran, C.; Stamos, M.; Wilson, S.E. Resolution of Hyperlipidemia after Laparoscopic Roux-en-Y Gastric Bypass. J. Am. Coll. Surg., 2006, 203, 24-29.
43. Loirdighi, N.; Ménard, D.; Levy, E. Insulin decreases chylomicron production in human fetal small intestine. BBA-Molecular Cell Research, 1992, 1175, 100-106.
44. Pavlic, M.; Xiao, C.; Szeto, L.; Patterson, B.W.; Lewis, G. F. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes, 2010, 59, 580-587.
45. Duez, H.; Lamarche, B.; Valéro, R.; Pavlic, M.; Proctor, S.; Xiao, C.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation, 2008, 117, 2369-2376.
46. Hein, G.; Baker, C.; Hsieh, J.; Farr, S.; Adeli, K. GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2-Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States. Diabetes, 2013, 62(2), 373-81.
47. Panjwani, N.; Mulvihill, E.E.; Longuet, C.; Yusta, B.; Campbell, J.E.; Brown, T.J.; Streutker, C.; Holland, D.; Cao, X.; Baggio, L.L.; Drucker, D.J. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology, 2013, 154, 127.
48. Wettergren, A.; Schjoldager, B.; Mortensen, P.E.; Myhre, J.; Christiansen, J.; Holst, J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci., 1993, 38, 665-673.
49. Kedees, M.H.; Guz, Y.; Grigoryan, M.; Teitelman, G. Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor. Peptides, 2013, 48, 36.
50. Orskov, C.; Rabenhøj, L.; Wettergren, A.; Kofod, H.; Holst, J. Tissue and plasma concentrations of amidated and glycineextended glucagon-like peptide I in humans. Diabetes, 1994, 43(4), 535-539.
51. Schirra, J.; Sturm, K.; Leicht, P.; Arnold, R.; Göke, B.; Katschinski, M. Exendin(9-39)amide is an antagonist of glucagonlike peptide-1(7-36)amide in humans. J. Clin. Invest., 1998, 101, 1421-1430.
52. Zander, M.; Madsbad, S.; Madsen, J.L.; Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet, 2002, 359, 824.
53. Wadden, D.; Cahill, F.; Amini, P.; Randell, E.; Vasdev, S.; Yi, Y.; Church, J.; Sun, G. Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutr. Metab., 2013, 10, 33-33.
54. Klop, B.; Elte, J., Willem F.; Cabezas, M. C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients, 2013, 5, 1218-1240.
55. Adeli, K.; Taghibiglou, C.; Van Iderstine, S.C.; Lewis, G.F. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc. Med., 2001, 11, 170-176.
56. Sparks, J.D.; Sparks, C.E.; Adeli, K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 2104.
57. Mohammad, H.N.; Abdul Momen, M.; Ban, K.; Al-Muktafi Sadi; Yu-Qing Zhou; Riazi, A.M.; Baggio, L.L.; Mark Henkelman, R.; Husain, M.; Drucker, D.J. GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice. Diabetes, 2009, 58, 975-983.
58. Mita, T.; Watada, H. Glucagon like Peptide-1 and atherosclerosis. Cardiovasc. Hematol. Agents Med. Chem. 2012, 10(4), 309-318.
59. Trevaskis, J.L.; Griffin, P.S.; Wittmer, C.; Neuschwander-Tetri, B.; Brunt, E.M.; Dolman, C.S.; Erickson, M. R.; Napora, J.; Parkes, D.G.; Roth, J.D. Glucagon-like peptide-1 (GLP-1) receptor agonism improves metabolic, biochemical and histopathological indices of nonalcoholic steatohepatitis (NASH) in mice. Am J Physiol-Gastr L., 2012, 302(8), G762-72.
60. Mells, J.E.; Fu, P.P.; Sharma, S.; Olson, D.; Cheng, L.; Handy, J.A.; Saxena, N.K.; Sorescu, D.; Anania, F.A. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastr. L., 2012, 302, G225-G235.
61. Lee, J.; Hong, S.; Chae, S.W.; Kim, D.H.; Choi, J.H.; Bae, J.C.; Park, S.E.; Rhee, E.; Park, C.; Oh, K.; Park, S.; Kim, S.; Lee, W. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PloS one, 2012, 7, e31394.
62. Parlevliet, E.T.; Schröder-van der Elst, J.P.; Corssmit, E.P.M.; Picha, K.; O'Neil, K.; Stojanovic-Susulic, V.; Ort, T.; Havekes, L.M.; Romijn, J.A.; Pijl, H. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J. Pharmacol. Exp. Ther., 2009, 328, 240-248.
63. Parlevliet, E.T.; Wang, Y.; Geerling, J.J.; Schröder-Van der Elst, J.P.; Picha, K.; O'Neil, K.; Stojanovic-Susulic, V.; Ort, T.; Havekes, L.M.; Romijn, J.A.; Pijl, H.; Rensen, P.C.N. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE3-Leiden mice. PloS one, 2012, 7, e49152.
64. Klonoff, D.C.; Buse, J.B.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Wintle, M.E.; Maggs, D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24, 275-275.
65. Horton, E.S.; Silberman, C.; Davis, K.L.; Berria, R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care, 2010, 33, 1759-1765.
66. Blonde, L.; Klein, E.J.; Han, J.; Zhang, B.; Mac, S.M.; Poon, T.H.; Taylor, K.L.; Trautmann, M.E.; Kim, D.D.; Kendall, D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab., 2006, 8, 436-447.
67. den Boer, M.; Voshol, P.J.; Kuipers, F.; Havekes, L.M.; Romijn, J.A. Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models. Arterioscl. Throm. Vas., 2004, 24, 644-649.
68. Schuppan, D.; Gorrell, M.D.; Klein, T.; Mark, M.; Afdhal, N.H. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Intern., 2010, 30, 795.
69. Grattagliano, I.; Portincasa, P.; Palmieri, V.O.; Palasciano, G. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can. Fam. Physician, 2007, 53, 857-863.
70. Preiss, D.; Sattar, N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. 2008, 115, 141.
71. Mishra, P.; Younossi, Z. Current treatment strategies for nonalcoholic fatty liver disease (NAFLD). Curr Drug Discov Technol., 2007, 4(2), 133-140.
72. Kugelmas, M.; Hill, D.B.; Vivian, B.; Marsano, L.; McClain, C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology, 2003, 38, 413-419.
73. Harrison, S.A.; Torgerson, S.; Hayashi, P.; Ward, J.; Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2003, 98, 2485.
74. Sjöström, L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int. J. Obes., 2008, 32, S93-S97.
75. Mummadi, R.R.; Kasturi, K.S.; Chennareddygari, S.; Sood, G.K. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol H, 2008, 6, 1396-1402.
76. Mathurin, P.; Hollebecque, A.; Arnalsteen, L.; Buob, D.; Leteurtre, E.; Caiazzo, R.; Pigeyre, M.; Verkindt, H.; Dharancy, S.; Louvet, A.; Romon, M.; Pattou, F. Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology, 2009, 137, 532-540.
77. Garber, A.J. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care, 2011, 34(2), S279-S284.
78. Ding, X.; Saxena, N.; Lin, S.; Gupta, N.; Anania, F. Obesity Pathogenesis; Exendin-4, a GLP-1 receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006, 43(1), 173-181.
79. Kern, M.; Klöting, N.; Niessen, H.G.; Thomas, L.; Stiller, D.; Mark, M.; Klein, T.; Blüher, M. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PloS one, 2012, 7, e38744.
80. Sharma, S.; Mells, J.E.; Fu, P.P.; Saxena, N.K.; Anania, F.A. GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy. PloS one, 2011, 6.
81. Flock, G.; Baggio, L.L.; Longuet, C.; Drucker, D.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes, 2007, 56, 3006-3013.
82. Astrup, A.; Carraro, R.; Finer, N.; Harper, A.; Kunesova, M.; Lean, M. E. J.; Niskanen, L.; Rasmussen, M. F.; Rissanen, A.; Rössner, S.; Savolainen, M. J.; Van Gaal, L.; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes, 2012, 36, 843-854.
83. Raun, K.; Pia, V.V.; Gotfredsen, C.F.; Golozoubova, V.; Rolin, B.; Lotte, B.K. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes, 2007, 56, 8-15.
84. Buse, J.B.; Klonoff, D.C.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Maggs, D.G.; Wintle, M.E. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three doubleblind, placebo-controlled trials. Clin. Ther., 2007, 29, 139-153.
85. Tushuizen, M.E.; Bunck, M.C.; Pouwels, P.J.; van Waesberghe, J.H., T.; Diamant, M.; Heine, R. J. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int, 2006, 26, 1015-1017.
86. Dunphy, J. L.; Taylor, R.G.; Fuller, PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol., 1998, 141, 179-186.
87. Blackmore, P.F.; Mojsov, S.; Exton, J.H.; Habener, J.F. Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes. FEBS Lett., 1991, 283, 7.
88. Gupta, N.A.; Mells, J.; Dunham, R.M.; Grakoui, A.; Handy, J.; Saxena, N.K.; Anania, F.A. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010, 51, 1584-1592.
89. Svegliati-Baroni, G.; Saccomanno, S.; Rychlicki, C.; Agostinelli, L.; De Minicis, S.; Candelaresi, C.; Faraci, G.; Pacetti, D.; Vivarelli, M.; Nicolini, D.; Garelli, P.; Casini, A.; Manco, M.; Mingrone, G.; Risaliti, A.; Frega, G. N.; Benedetti, A.; Gastaldelli, A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011, 31, 1285-1297.
90. Aviv, V.; Meivar-Levy, I.; Rachmut, I.H.; Rubinek, T.; Mor, E.; Ferber, S. Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J. Biol. Chem. 2009, 284, 33509-33520.
91. Redondo, A.; Trigo, M.V.; Acitores, A.; Valverde, I.; Villanueva-Peñacarrillo, M. L. Cell signalling of the GLP-1 action in rat liver. Mol. Cell. Endocrinol., 2003, 204, 43-50.
92. Vahl, T.P.; Tauchi, M.; Durler, T.S.; Elfers, E.E.; Fernandes, T.M.; Bitner, R.D.; Ellis, K.S.; Woods, S.C.; Seeley, R.J.; Herman, J.P.; D'Alessio, D.A. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology, 2007, 148, 4965-4973.
93. Knauf, C.; Cani, P.D.; Perrin, C.; Iglesias, M.A.; Maury, J.F.; Bernard, E.; Benhamed, F.; Grémeaux, T.; Drucker, D.J.; Kahn, C.R.; Girard, J.; Tanti, J.F.; Delzenne, N.M.; Postic, C.; Burcelin, R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest., 2005, 115, 3554-3563.
94. Kastin, A.J.; Akerstrom, V.; Pan, W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18, 7-14.
95. Vrang, N.; Larsen, P.J. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog. Neurobiol., 2010, 92, 442-462.
96. Nishizawa, M.; Nakabayashi, H.; Kawai, K.; Ito, T.; Kawakami, S.; Nakagawa, A.; Niijima, A.; Uchida, K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J. Auton. Nerv. Syst., 2000, 80, 14-21.
97. Fliers, E.; Fleur, L., S.E.; Yi, C.X.; Kalsbeek, A. The role of the autonomic nervous liver innervation in the control of energy metabolism. BBA Mol. Basis Dis. 2010, 1802, 416-431.
98. Tomas, E.; Stanojevic, V.; Habener, J. F. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul. Pept., 2011, 167, 177-184.
99. Farr, S.; Adeli, K. Incretin-based therapies for the treatment of postprandial dyslipidemia in insulin-resistant states. Curr. Opin. Lipidol., 2012, 23, 56-61.